title: [The use of cytoflavin in combined neurometabolic therapy of acute cerebral insufficiency associated with acute poisoning with neurotropic poisons].
abstract: Examination and treatment of 262 patients with severe acute intoxication by neurotropic poisons and unaffected oxygen delivery system showed that inclusion of cytoflavin in combined neurometabolic therapy of acute cerebral insufficiency significantly reduced severity of metabolic disorders. Specifically, tissue hypoxy, endotoxicosis, lipid peroxidation activity, and immunosuppression decreased while antioxidative protection and clinical picture were improved. Duration of comatose state and artificial lung ventilation was reduced from 64.5 +/- 15.1 to 28.8 +/- 10.2 hours and that of critical condition from 117.2 +/- 17.2 to 63.7 +/- 9.2 hours. Overall lethality dropped from 16 to 9.9%.
authors.forename: M V
authors.initials: MV
authors.lastname: Aleksandrov
authors.forename: S A
authors.initials: SA
authors.lastname: Vasil'ev
authors.forename: O A
authors.initials: OA
authors.lastname: Kuznetsov
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Andrianov
authors.forename: I A
authors.initials: IA
authors.lastname: Shikalova
authors.forename: A T
authors.initials: AT
authors.lastname: Loladze
authors.forename: B V
authors.initials: BV
authors.lastname: Batotsyrenov
mesh_terms: D000208:Acute Disease; D017252:CD3 Complex / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D016827:CD8 Antigens / Q000097:blood; D003128:Coma / Q000209:etiology / Q000628:therapy; D016638:Critical Illness; D004338:Drug Combinations; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D002534:Hypoxia, Brain / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008214:Lymphocytes / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D009536:Niacinamide / Q000627:therapeutic use*; D011041:Poisoning / Q000150:complications / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D012121:Respiration, Artificial; D013386:Succinates / Q000627:therapeutic use*
chemical_list: D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D004338:Drug Combinations; D018696:Neuroprotective Agents; D015375:Receptors, Interleukin-2; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate